COST-EFFECTIVENESS ANALYSIS OF INSULIN REGIMEN ON TYPE 2 DIABETES MELLITUS OUTPATIENT IN DENPASAR MUNICIPALITY by Larasanty, Luh Putu Febryana et al.
Vol 11, Issue 1, 2018
Online - 2455-3891 
Print - 0974-2441
COST-EFFECTIVENESS ANALYSIS OF INSULIN REGIMEN ON TYPE 2 DIABETES MELLITUS 
OUTPATIENT IN DENPASAR MUNICIPALITY
LUH PUTU FEBRYANA LARASANTY*, MADE ARY SARASMITA, I GUSTI NGURAH AGUNG DEWANTARA PUTRA
Department of Pharmacy, Faculty of Mathematics and Basic Science, Udayana University, Bali, Indonesia. Email: febryana@unud.ac.id
Received: 25 March 2017, Revised and Accepted: 28 September 2017
ABSTRACT
Objective: Insulin is one of the antidiabetic agents that available for the treatment of type 2 diabetes mellitus (T2DM) patients. Insulin has several 
types of formulation, with its cost and effectiveness. The aim of this study was to compare the cost-effectiveness of insulin regimen in the therapy 
management of T2DM outpatient.
Methods: Cost-effectiveness analysis has been done by calculating the average cost-effectiveness ratio (ACER) and incremental cost-effectiveness 
ratio (ICER) of each insulin regimens. Effectiveness was measured by improvement of fasting blood glucose, postprandial blood glucose, and HbA1c 
value. The total cost of insulin regimen was calculated from direct medical cost, direct nonmedical cost, and indirect nonmedical cost.
Results: Overall, 42 patients meet the inclusion criteria were included this study. There were four insulin regimens compared, namely, insulin detemir, 
premixed insulin aspart, insulin aspart, and a combination of insulin aspart + insulin glargine. The combination of insulin aspart + insulin glargine 
provides pre-eminent therapy effectiveness (58.82%), whereas insulin detemir regimen has the lowest total cost (102.62 USD). Calculation of ACER 
showed that insulin aspart has the lowest ACER value, in an amount of 1.91 USD per percentage of effectiveness. Based on ICER value, insulin aspart 
was the better choice compared to the combination of insulin aspart + insulin glargine (0.18 USD vs. 0.82 USD).
Conclusion: The variation of therapeutic effectiveness and total cost was observed in the management of T2DM outpatient. Based on ACER and ICER 
value, insulin aspart was the most cost-effective insulin compared to another insulin regimen on the study.
Keywords: Average cost-effectiveness ratio, Cost-effectiveness analysis, Incremental cost-effectiveness ratio, Insulin, Type 2 diabetes mellitus.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is one of the degenerative diseases 
that become a risk factor for cardiovascular diseases such as stroke, 
ischemic heart disease, and chronic kidney diseases [1]. This disease 
is a chronic illness that requires high treatment costs. In 2012, medical 
expenses spent for the treatment of T2DM patients in the United States 
reached 245 billion dollars. Patient with T2DM paid medical costs 
2.3 times higher than for those without diabetes. Most of medical costs 
incurred by T2DM patients used to direct medical costs associated with 
patient treatment, including antidiabetic drug supply [2,3].
Insulin is one of antidiabetic agent which plays an important role for the 
treatment of T2DM patients. Insulin analogs were developed to mimic 
the basal and bolus components of physiologic insulin secretion [4,5]. 
There are several types of insulin formulations such as rapid-acting 
insulin, short-acting insulin, long-acting insulin, and premixed insulin 
formulation [6]. The differences of formulations produce a different 
price for each unit of insulin result in a difference in total costs for each 
treatment regimen [7-9]. We analyzed a comparison between cost and 
effectiveness the used of insulin therapy regimens in management of 
T2DM outpatient in Denpasar Municipality.
METHODS
Study design
This study is a pharmacoeconomic research of insulin regimen usage in 
T2DM outpatient at the two general hospitals in Denpasar municipality, 
Bali, Indonesia. Type of this pharmacoeconomic study was cost-
effectiveness analysis with average cost-effectiveness ratio (ACER) 
and incremental cost-effectiveness ratio (ICER) calculation. ACER was 
obtained by dividing the total cost by the percentage of therapeutic 
effectiveness. ICER calculated by dividing differences of the total cost to 
the differences in the effectiveness of a therapy regimen [10-12].
Inclusion and exclusion criteria
The patient included in this study had uncontrolled blood glucose 
level, received insulin regimen without oral anti-diabetes drugs, 
live in Denpasar municipality, and willing to participate in research. 
Patient with comorbid diseases, pregnancy, use oral contraception, or 
another drug that can affect blood glucose level were excluded from 
participating in this study. All patients who met the assigned criteria 
were included as research subjects.
Data collection
Clinical effectiveness of insulin regimen was measured by fasting 
blood glucose (FBG) level, postprandial blood glucose (PBG) level, and 
glycated hemoglobin (HbA1c) value. Every patient had been followed 
up for three consecutive months. FBG and PBG parameters measured 
at baseline (initial of study) and every month during the study. Glycated 
hemoglobin measured at the baseline and the 3rd month of study. 
Examination conducted in the clinical laboratory of each hospital. Data 
of effectiveness parameters were taken from laboratory results sheet at 
patient medical records.
The total cost of insulin regimen calculated from direct medical 
cost (doctor service fee, insulin and its equipment costs, and cost of 
laboratory examination), direct nonmedical cost (administration fees 
and transportation), and indirect nonmedical cost (loss of salary/
earnings for absent from work). Data for doctor service charge, price 
of each type of insulin and its equipment costs, the cost of laboratory 
examination, and administration fees taken from administration billing 
and pharmacy medical report. Transportation cost calculated from 
round trip mileage from patient’s home to the hospital multiplied by 
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transportation operating cost in Denpasar municipality. Loss of salary/
earnings for absent from work was obtained from patient’s work 
history.
Data analysis
Clinical effectiveness parameters (FBG, PBG, and HbA1c) are presented 
as the mean ± standard deviation (SD). Change in the outcome values 
(baseline to 3-month follow-up result) is calculated as percentages (%) 
reduction from baseline data. Statistical analysis of clinical parameters 
by analysis of variance followed with LSD test. The cost for each clinical 
outcome derived from a total cost of insulin regimen divided by the 
total reduction changes of each parameter. Total clinical effectiveness 
was calculated based on the number of patients in each regimen group 
which meet the clinical target (FBG 80-130 mg/dL, PBG <180 mg/dL, 
and HbA1c <7% [13]divided by the total patient in each regimen group. 
Total clinical effectiveness is presented in percentage (%) effectiveness. 
ACER and ICER calculated based on ACER and ICER equation from 
the World Health Organization guide to cost-effectiveness analysis 
(CEA) [12].
Ethical approval
This study has received ethical approval from the Ethics Committee 
of Sanglah General Hospital number 1278/UN.14.2/Litbang/2016. 




A total of 184 T2DM patient records were available from the internal 
medicine outpatient department. 43 patients were meet inclusion and 
exclusion criteria and were included in this study. From 43 patients, one 
patient was excluded from the entire analysis because lost to follow-up 
at monthly check up, remaining 42 patients as the study subjects. Those 
patients then followed up for 3 months to assess insulin effectiveness 
(Fig. 1).
Clinical effectiveness of insulin regimen
There were four types of insulin regimen that mostly used by T2DM 
outpatient in general hospital at Denpasar municipality. They were 
insulin aspart (NovoRapid®), insulin detemir (Levemir®), premixed 
insulin aspart 30% and protamine crystallized insulin aspart 70% 
(NovoMix®), and a combination of insulin aspart (NovoRapid®) plus 
insulin glargine (Lantus®). Insulin regimen outcomes from baseline 
to 3-month follow-up period are shown in Table 1. Based on FBG, PBG 
and HbA1c measurements from baseline to the 3rd-month follow-up, 
showed that the used of insulin therapy could provide a reduction in the 
patient’s blood glucose level. There is no significant difference (p>0.05) 
in the outcome at the 3rd month of follow-up for the FBG, PBG, and 
HbA1c between each regimen group.
The highest total reduction of clinical outcome parameters obtained 
in insulin aspart regimen group with the total reduction in FBG was 
50.65%, PBG was 37.24%, and HbA1c was 35.90%. A statistically 
significant differences (p<0.01) in a total reduction of FBG and HbA1c 
were observed between each treatment group. While for PBG reduction, 
the significant differences (p<0.05) only observed in insulin aspart 
regimen versus premixed insulin regimen and combination insulin 
aspart + insulin glargine regimen versus premixed insulin regimen.
Total % effectiveness of insulin regimen is summarized in Table 2. 
The combination of insulin aspart + insulin glargine gives the highest 
total effectiveness (58.82%) compared to the other insulin regimen. 
Insulin aspart regimen which gives a highest total reduction on each 
parameter was at the second position with overall achievement on total 
effectiveness as much as 57.14%.
Cost-effectiveness measurement
Differences between clinical outcome of each insulin regimen and 
differences of the total cost result in different average cost for each 
clinical parameter. Calculation of the average cost for each reduction of 
clinical outcomes can be seen in Table 2. Insulin aspart has the lowest 
average cost for each clinical parameter reduction, whereas premixed 
insulin was the regimen with highest average cost. The average cost 
of every mg/dL reduction of FBG was 0.86 USD for insulin aspart 
versus 10.62 USD for premixed insulin. For PBG, an average cost of 
every mg/dL reduction was 0.99 USD for insulin aspart versus 19.24 
USD for premixed insulin. Every percentage (%) reduction in HbA1c of 
insulin aspart required an average cost of 25.88 USD versus 518.13 USD 
for premixed insulin.
Calculation of ACER can be seen in Table 2. Each of insulin regimen 
rank in ascending order based on its cost. Insulin aspart has the 
lowest ACER (1.91 USD), and premixed insulin has the highest ACER 
(6.34 USD). Premixed insulin was strongly dominated regimen because 
has increased cost and reduced effect compared with insulin detemir. 
The strongly dominated regimen can be excluded from analysis. Insulin 
detemir, insulin aspart, and the combination of insulin aspart + insulin 
glargine then calculated for ICER value (Table 3). The combination of 
insulin aspart + insulin glargine was more effective and more costly 
than insulin detemir, and insulin aspart results in higher ICER value 
compared with insulin aspart (0.82 and 15.01 vs. 0.18).
DISCUSSION
Insulin is the choice of treatment in patient with T2DM with real specific 
symptoms and/or increased levels of blood glucose or HbA1c [14]. Our 
result study suggests that treatment with insulin aspart is associated 
with a statistically significant reduction in FBG, PBG, and HbA1c 
compared with another regimen (p≤0.05), even though there is no 
statistically significant difference between final result value on the 
3rd month of each regimen. Insulin aspart is a bolus insulin that used 
to resolve the increase in glucose level after meals and maintain 2 h 
postprandial glucose level [5,14]. It also provides a better glycemic 
control which reflected in the HbA1c value [4]. The results of this study 
also showed that insulin aspart has an influence on changes of FBG 
value.
There were 57.14% of patients in insulin aspart regimen achieved the 
clinical effectiveness target. This result is lower when compared with 
the effectiveness obtained by the combination of insulin aspart + insulin 
glargine but was much better when compared to the result of insulin 
detemir. The combination of insulin aspart + insulin glargine gave the 
highest effectiveness as much as 58.82%. Swinnen et al. defined that 
adding a bolus insulin to the patient with one daily dose basal insulin 
can improve the effectiveness of insulin regimen. Therapy with both 
basal and prandial insulin results in better glycemic control than basal 
insulin treatment alone [15,16].
Total cost calculation at Table 2 showed that the usage of insulin 
detemir provides the lowest total cost and the highest total cost was 
insulin aspart + insulin glargine combination. One of the factors which 
influence the total cost of insulin regimen was the unit price of insulin 
and the amount of insulin that is used by the patient per month. Insulin 
detemir is a once daily basal insulin. Insulin basal is the most convenient 
184 patients
Number of patient meet inclusion and exclusion criteria 43 patients
Lost to follow-up 1patients
Total number of complete records available for analysis 42 patients
Total number of outpatient patient with type 2 diabetes mellitus
Fig. 1: Patient disposition
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insulin regimen and gave much lower cost [14,17]. The combination 
of insulin aspart + insulin glargine means using two types of insulin 
simultaneously, thus causing accumulation of total cost incurred by the 
patient.
CEA is a pharmacoeconomic study that compares the relative difference 
of cost and outcome of different treatment strategies [18]. CEA results 
are ACER and ICER value. Calculation of average cost ratio for each 
reduction of clinical outcomes and ACER demonstrated the superiority 
of insulin aspart compared to the three other insulin regimens. ACER 
was calculated by dividing the average cost of treating the patient with 
a regimen by average outcome per patient [12,19]. Although ACER was 
easy to calculate, they cannot be used to set priorities and decision for 
pharmacoeconomics consideration because ACER does not compare the 
costs and outcomes of between all alternatives [19]. Implementation of 
ACER value may use as device decision rule based on a fixed budget to 
maximize total effectiveness [18].
ICER described an additional cost per additional health outcome. It 
compares the difference between the costs and health outcome of two 
alternative interventions that compete for the same resources [20]. 
There were only three regimens that calculated for ICER value 
(Table 3). Premixed insulin was excluded from the analysis because 
of strongly dominated. Insulin aspart and the combination of insulin 
aspart + insulin glargine were a comparator and compared against 
insulin detemir. Insulin detemir was the most relevant alternative 
because of insulin basal was the standard intervention based on the 
clinical treatment guidelines [14,20].
The result of ICER value can be used in decision-making for choosing 
regimen therapy alternatives [20]. Insulin aspart has lower ICER value 
compared to the combination of insulin aspart + insulin glargine. This 
study suggests that use of insulin aspart has an additional cost per 
additional health outcome less than the use of the combination of 
insulin aspart + insulin glargine, compared to the conventional therapy 
(insulin detemir). When willingness to pay is above the insulin detemir 
cost and its need to increase the treatment effectiveness, insulin aspart 
is a better option compared to the combination of insulin aspart + 
insulin glargine.
Limitation of the study
Limitation of this study was its small sample size and short duration. 
In addition, glycemic and HbA1c variability at baseline were not 
measured for its normality and homogenity. A long-term study with 
larger sample size must be carried out to evaluate a long-term clinical 
effect of insulin therapy. Treatment effectiveness in a long-term study 
can also be measured in patient quality of life. It needs to measure 
hypoglycemia-induced insulin as hypoglycemic episodes were most 
commonly reported adverse events with insulin and one of parameters 
that affect insulin therapy effectiveness [21]. Cardiovascular, micro- and 
macrovascular complication can also be measured in the long-term 
study. The emergence of hypoglycemic events and complications can 
Table 1: Changes in insulin regimen outcomes from baseline to 3-month follow-up period
Insulin regimen Parameters Baseline (mean±SD) 3-month follow-up (mean±SD) % Reduction
Insulin aspart FBG 251.0±62.4 123.9±34.5 50.65*
PBG 295.4±65.9 185.4±54.7 37.24**
HbA1c 11.8±2.5 7.5±1.9 35.90*
Insulin detemir FBG 252.6±72.8 147.4±42.0 41.65*
PBG 306.8±75.3 218.2±51.2 28.88
HbA1c 12.1±2.9 8.6±1.8 29.10*
Premixed insulin FBG 146.3±40.3 136.7±34.2 6.61*
PBG 221.3±73.4 216.0±58.1 2.41**
HbA1c 7.7±2.1 7.5±1.3 2.57*
Insulin aspart + 
insulin glargine
FBG 197.4±69.7 138.2±36.7 29.98*
PBG 296.2±66.9 194.4±85.9 34.37**
HbA1c 8.8±2.7 7.2±1.1 18.04*
FBG: Fasting blood glucose is in mg/dL, PBG: Post prandial blood glucose is in mg/dL, HbA1c: Glycated haemoglobin is in %, *statistically significant differences 
(p<0.01), **statistically significant differences (p<0.05)
Table 3: ICER of insulin regimen




Insulin detemir vs. insulin aspart 6.69 37.14 0.18
Insulin detemir vs. insulin aspart + insulin glargine 31.92 38.82 0.82
Insulin aspart vs. insulin aspart + insulin glargine 25.23 1.68 15.01
ICER: Incremental cost effectiveness ratio
Table 2: Total cost, average cost for unit outcome, and ACER
Parameters Insulin regimen
Insulin detemir Premixed insulin Insulin aspart Insulin aspart + insulin glargine
Total cost* 102.62 105.63 109.31 134.54
Average cost per unit outcome FBG (USD/mgdl−1) 1.28 10.62 0.86 1.79
PBG (USD/mgdl−1) 1.52 19.24 0.99 1.04
HbA1c (USD/% HbA1c) 38.13 518.13 25.88 66.46
Total clinical effectiveness (%) 20.00 16.67** 57.14 58.82
ACER (USD/%) 5.13 6.34 1.91 2.29
*Cost is measured in IDR and converted to USD with currency 13,333.00 IDR = 1 USD, **premixed insulin is strongly dominated (increased cost and reduced effect), 
ACER: Average cost effectiveness ratio
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affect an amount of insulin therapy costs so that it will have an influence 
on the pharmacoeconomic analysis.
This study limitation can be a premise for further pharmacoeconomic 
study with longer study period and larger sample size. To ensure 
adequate cost analysis, it needs to develop a cost analysis based on 
health-care regulation. Pharmacoeconomic study in Indonesia needs 
to be developed considering of the economic burden of disease and 
retrieve of the National Health Insurance System has been set by the 
Indonesian government.
CONCLUSION
Based on ACER and ICER value, insulin aspart has an eminence in CEA 
compared to insulin detemir, premixed insulin, and the combination of 
insulin aspart + insulin glargine. We need further study to assess the 
long-term impact of insulin use and its economic burden on Indonesian 
health-care system.
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